All In Biotech

NDA 022119 · Feinstein

Ammonia N 13

Ammonia N-13 · Intravenous · Radioactive Diagnostic Agent

Novel

Last checked: Nov 21, 2026Latest source record: Jan 5, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

Aug 23, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

5

0 Phase 3, 2 recruiting

FAERS reports

57

43 serious, 8 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2019.

Ammonia N 13 Injection is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. Ammonia N 13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 23, 2007 Original approval · Type 1 - New Molecular Entity NovelLetterReview
1 products under this application
  • AMMONIA N 13 · AMMONIA N-13 30mCi-300mCi/8ML (3.75-37.5mCi/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ammonia N-13" as an intervention, any sponsor and status, largest first.

All 5 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug abuse7
  • cough6
  • depression6
  • drug ineffective6
  • chest pain5
  • dyspnoea5
  • nausea5
  • suicide attempt5
  • vomiting5
  • accidental exposure to product4
  • drug hypersensitivity4
  • eye irritation4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20073
20101
20113
20121
20133
20142
20153
20164
20171
20185
20196
20203
20213
20222
20233
20243
20259
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Feinstein

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.